P

P

Lord Jesus Christ Says...

The thief cometh not, but for to steal, and to kill, and to destroy: I am come that they might have life, and that they might have it more abundantly. I am the good shepherd: the good shepherd giveth his life for the sheep.

6 Dec 2017

Share market-A future Pharma giant in throw away price.

Watch this share. It is a dark horse, now available on throw away price (36/50). Please read the Chairman’s speech and verify other details in the company site.It will be a long term bet.
From the Chairman's Desk (MARSANS PHARMA)
It all started with a vision to create a Global Pharmaceutical company. We are working towards this goal with utmost enthusiasm and commitment. As a result, Marksans Pharma has successfully established itself as a trustworthy name in the pharmaceutical world.
OUR FOCUS MARKETS
We have a special focus towards exports markets like US, Canada, Europe, and Australia. Through ongoing research and product development, we have been able to grow from strength-to-strength in these markets and are taking giant strides each day! Having established our presence in these markets, we are now expanding our focus towards emerging markets where we have over 350+ approved products and 200+ products pending approvals.
OUR CAPABILITIES
Our formulation manufacturing plant at Verna, Goa, has state-of-the-art facilities and is specially designed to meet the global statutory requirements. This plant is US FDA approved and has approvals from esteemed organizations such as US FDA, UK MHRA, Australian TGA. We also have a WHO GMP certificate. This factory has the largest Soft gel manufacturing facility in India. This is a 100% EOU. To strengthen our global efforts, a full-fledged R&D centre has been set up along with the manufacturing facility at Verna, Goa.

EXPANSIONS
As far as inorganic growth is concerned, we at Marksans are aggressive to pursue our vision. To gain a foothold in the Australasia region we acquired Nova Pharmaceuticals Australasia Pty Ltd., in Europe, we acquired Bell, Sons & Co (Druggists) Ltd. a UK MHRA approved formulation manufacturing and marketing company exporting liquid, ointment and powder to 50 countries globally. Further, in order to build capabilities across the entire value chain, we acquired Relonchem Ltd., which markets and distributes high-end prescription products in UK.
These acquisitions give us an opportunity to leverage the low cost manufacturing base in India and further enhance the profitability by supplying to global markets.
WAY AHEAD
There are changes, challenges and opportunities that lie ahead for Marksans. In order to seize these opportunities, we are putting forth a concerted and systematic effort powered by expert and professional planning and implementation. We continue to acquire and develop winning strengths and capabilities in our drive towards becoming a research-driven Indian pharmaceutical company operating on a global scale.
The past few years, we have gained momentum in each of these thrust areas with important gains in marketing, globalization and research - especially in terms of creating essential capabilities for the challenges ahead. With this, all of us are committed to explore our true potential and face the challenges on our way to attain important milestones.
We know that a lot remains to be done. Our early success has given us the confidence, respect, and credibility. Real work has started; we will see the fruits of the same in the months and years to come.
Marksans will soon transform itself into a global pharmaceutical giant.

Mr. Mark Saldanha
Managing director and CEO

No comments:

Post a Comment